Last reviewed · How we verify
NCT06272838
Biodex Balance System in Patients With Parkinson's Disease
NA trial testing Biodex balance system in Parkinson Disease in 60 participants. Status unknown.
14 September 2024
Quick facts
| Lead sponsor | Kirsehir Ahi Evran Universitesi |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 28 February 2024 |
| Primary completion | 14 September 2024 |
| Estimated completion | 14 October 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Biodex balance system
- The conventional balance exercise program
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Kirsehir Ahi Evran Universitesi — full company profile →
Who can join
Adults 40 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Conventional balance exercises are an effective rehabilitation method applied in routine rehabilitation programs for Parkinson's patients. With technological developments, balance exercises
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06272838
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biodex balance system
Trials testing the same drug.
- NCT06606392 — Effect of Biodex Balance Training and Short Foot Exercise on Myoelectric Activity of Paraspinal Muscles in Subjects with · NA · not yet recruiting
- NCT06978517 — Effect of Postural Stability System Comparison to Nintendo Wii Fit Balance Training on Fall Risk and Postural Stability · NA · completed
- NCT04943614 — Biodex Balance System Training in Diabetic Neuropathy · NA · completed
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Kirsehir Ahi Evran Universitesi trials
Trials by the same sponsor.
- NCT07506915 — The Effect of Cognitive Behavioral Therapy · NA · enrolling by invitation
- NCT07502248 — PENG Block With or Without PPD Block for Postoperative Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
- NCT07438392 — Tecar Therapy in Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07450742 — Digital Storytelling and Mother's Knowledge and Attitudes Towards Newborn Screning · NA · not yet recruiting
- NCT07414017 — Comparison of Focus of Attention in Virtual Reality-Based Exercise Training in Older Adults With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06272838 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kirsehir Ahi Evran Universitesi
- Last refreshed: 22 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06272838.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing